IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Igα/β

被引:103
作者
Waisman, Ari [1 ]
Kraus, Manfred
Seagal, Jane
Ghosh, Snigdha
Melamed, Doron
Song, Jian
Sasaki, Yoshiteru
Classen, Sabine
Lutz, Claudia
Brombacher, Frank
Nitschke, Lars
Rajewsky, Klaus
机构
[1] Univ Cologne, Inst Genet, D-50674 Cologne, Germany
[2] Univ Cologne, Ctr Mol Med, D-50674 Cologne, Germany
[3] Univ Mainz, Dept Med 1, D-55131 Mainz, Germany
[4] Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[6] Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany
[7] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Dept Immunol, IL-31096 Haifa, Israel
[8] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel
[9] Max Planck Inst Immunobiol, D-79011 Freiburg, Germany
[10] Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7925 Cape Town, South Africa
关键词
D O I
10.1084/jem.20062024
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We describe a mouse strain in which B cell development relies either on the expression of membrane-bound immunoglobulin ( Ig) gamma 1 or mu heavy chains. Progenitor cells expressing gamma 1 chains from the beginning generate a peripheral B cell compartment of normal size with all subsets, but a partial block is seen at the pro- to pre-B cell transition. Accordingly, gamma 1-driven B cell development is disfavored in competition with developing B cells expressing a wild-type ( WT) IgH locus. However, the mutant B cells display a long half-life and accumulate in the mature B cell compartment, and even though partial truncation of the Ig alpha cytoplasmic tail compromises their development, it does not affect their maintenance, as it does in WT cells. IgG1-expressing B cells showed an enhanced Ca2+ response upon B cell receptor cross-linking, which was not due to a lack of inhibition by CD22. The enhanced Ca2+ response was also observed in mature B cells that had been switched from IgM to IgG1 expression in vivo. Collectively, these results suggest that the gamma 1 chain can exert a unique signaling function that can partially replace that of the Ig alpha/beta. heterodimer in B cell maintenance and may contribute to memory B cell physiology.
引用
收藏
页码:747 / 758
页数:12
相关论文
共 40 条
[21]   INDUCTION OF TOLERANCE TO AN IGG AUTOANTIBODY [J].
OFFEN, D ;
SPATZ, L ;
ESCOWITZ, H ;
FACTOR, S ;
DIAMOND, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (17) :8332-8336
[22]   Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses [J].
Oliver, AM ;
Martin, F ;
Gartland, GL ;
Carter, RH ;
Kearney, JF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) :2366-2374
[23]   Gene dose-dependent maturation and receptor editing of B cells expressing immunoglobulin (Ig)G1 or IgM/IgG1 tail antigen receptors [J].
Pogue, SL ;
Goodnow, CC .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (06) :1031-1043
[24]   B-CELL ANTIGEN RECEPTORS [J].
RETH, M .
CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (01) :3-8
[25]  
ROARK JH, 1995, J IMMUNOL, V154, P4444
[26]   CELL AUTONOMOUS EXPRESSION OF IGD IS NOT ESSENTIAL FOR THE MATURATION OF CONVENTIONAL B-CELLS [J].
ROES, J ;
RAJEWSKY, K .
INTERNATIONAL IMMUNOLOGY, 1991, 3 (12) :1367-1371
[27]   Fidelity and infidelity in commitment to B-lymphocyte lineage development [J].
Rolink, AG ;
Schaniel, C ;
Busslinger, M ;
Nutt, SL ;
Melchers, F .
IMMUNOLOGICAL REVIEWS, 2000, 175 :104-111
[28]   IMMUNOGLOBULIN GAMMA-2B TRANSGENES INHIBIT HEAVY-CHAIN GENE REARRANGEMENT, BUT CANNOT PROMOTE B-CELL DEVELOPMENT [J].
ROTH, PE ;
DOGLIO, L ;
MANZ, JT ;
KIM, JY ;
LO, D ;
STORB, U .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2007-2021
[29]   LAMBDA-5, BUT NOT MU, IS REQUIRED FOR B-CELL MATURATION IN A UNIQUE GAMMA-2B TRANSGENIC MOUSE LINE [J].
ROTH, PE ;
KURTZ, B ;
LO, D ;
STORB, U .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (03) :1059-1070
[30]  
Samardzic T, 2002, EUR J IMMUNOL, V32, P561, DOI 10.1002/1521-4141(200202)32:2<561::AID-IMMU561>3.0.CO